{"groups":[{"description":"Phase II dose extension cohort in pre-treated EGFR T790M mutation positive patients in AZD9291 80mg tablet.","id":"FG000","title":"AZD9291 80mg Extension"},{"description":"Pre-treated patient cohort in doses 20, 40, 80, 160 and 240mg AZD9291 capsule.","id":"FG001","title":"Dose Escalation"},{"description":"Pre-treated EGFR T790M mutation positive (by central testing) patient cohort. Dose groups were expanded to include more patients.","id":"FG002","title":"Dose Expansion"},{"description":"Cohort of patients receiving first-line treatment for EGFRm advanced NSCLC, in 80mg and 160mg AZD9291 capsule.","id":"FG003","title":"First Line"},{"description":"US-only cohort of pre-treated EGFR patients receiving the tablet formulation of AZD9291 (80 mg).","id":"FG004","title":"80mg Tablet"},{"description":"Japan-only cohort of patients (EGFR T790M mutation status determined from cytology samples) receiving AZD9291 80 mg tablet.","id":"FG005","title":"Japan Cytology"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"38"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"104"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"4"}],"type":"Objective Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}],"type":"Other (not specified)"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"201"},{"groupId":"FG001","numSubjects":"31"},{"groupId":"FG002","numSubjects":"271"},{"groupId":"FG003","numSubjects":"60"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"28"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"139"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"115"},{"groupId":"FG003","numSubjects":"50"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"22"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"156"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"603 patients were enrolled and received treatment.","recruitmentDetails":"Patients recruited to different cohorts. Dose escalation cohort of pre-treated patients in 5 dose groups. Dose expansion cohort (pre-treated) in same 5 dose groups. First line patient cohort. 80mg tablet cohort of pre-treated patients. Japan-only cohort (EGFR T790M+ by cytology). Phase II extension cohort in pre-treated EGFR T790M+ patients."}